Values First Advisors Inc. Has $2.12 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Values First Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,992 shares of the biopharmaceutical company’s stock after purchasing an additional 202 shares during the period. Alnylam Pharmaceuticals makes up approximately 1.2% of Values First Advisors Inc.’s portfolio, making the stock its 17th biggest holding. Values First Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,116,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ALNY. Jennison Associates LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $61,160,000. Strategic Financial Concepts LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $41,529,000. Eventide Asset Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 157.9% in the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares during the last quarter. Finally, Telemark Asset Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $27,503,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ALNY has been the topic of a number of research analyst reports. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Raymond James boosted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Trading Down 1.8 %

Alnylam Pharmaceuticals stock opened at $268.99 on Wednesday. The stock has a market cap of $34.69 billion, a P/E ratio of -102.67 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm’s fifty day moving average price is $253.54 and its 200-day moving average price is $262.97. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.